The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+T-cell line with potent in vivo graft-versus-leukemia properties

Blood

Volumn 89, Issue 9, 1997, Pages 3477-3485

  Boyer, Michael W ^a   Vallera, Daniel A ^b   Taylor, Patricia A ^b   Gray, Gary S ^b   Katsanis, Emmanuel ^b   Gorden, Keith ^b   Orchard, Paul J ^b   Blazar, Bruce R ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; RECOMBINANT PROTEIN;

ACUTE DISEASE; ANIMAL; ARTICLE; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EXPERIMENTAL LEUKEMIA; FEMALE; GENE TRANSFER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; MORTALITY; MOUSE; MYELOID LEUKEMIA; SURVIVAL;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD80; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE TRANSFER TECHNIQUES; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOID; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0031132831     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.9.3477     Document Type: Article

References (28)

1. Dusenbery KE, Daniels KA, McClure JS, McGlave PB, Ramsay NK, Blazar BR, Neglia JP, Kersey JH, Woods WG: Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiât Oncol Biol Phys31:119, 1995
2. Petersen FB, Lynch MHE, Clift RA, Applebaum FR, Sanders JE, Bensinger WI, Benyunes MC, Doney K, Fefer A, Martin P, Storb R, Rowley S, Sullivan KM, Witherspoon R, Weiden P, Thomas ED, Fisher L, Hansen JA, Buckner CD: Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 11:1353, 1993
3. Brenner MK, Rill DR, Moen RC, Krance RA, Heslop HE, Mirro J Jr, Anderson WF, Ihle JN: Gene marking and autologous bone marrow transplantation. Ann NY Acad Sci 716:204, 1994
4. McGlave PB, Haake RJ, Bostrom BC, Brunning R, Hurd DD, Kim TH, Nesbit ME, Vercellotti GM, Weisdorf D, Woods WG: Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 72:1512, 1988
5. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA: Effect of HLA incompatibility on graftversus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 29:79, 1990
6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, B on in MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
7. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobson N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, deWitte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995
8. Falkenburg JHF, Faber LM, van den Elshout M, van Luxemburg-Heijs SAP, Hooftman-den Otter A, Smit WM, Willemze R: Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother 14:305, 1993
9. + T cell immune response to murine myeloid leukemia. Blood 85:2498, 1995
10. Schwanz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interIeukin-2 production and immunotherapy. Cell 71:1065, 1992
11. Azuma M, Cayabyab M, Buck D, Philips JH, Lanier LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting lymphocytes. J Exp Med 175:353, 1992
12. Katsanis E, Xu Z, Bausero M, Dancisak BB, Gorden KB, Davis G, Gray OS, Orchard PJ, Blazar BR: B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther 2:39, 1995
13. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Gribben JJ, Ng JW, Kim J, Goldberg JM, Hathcock KGL, Lombard LA, Wang S, Gray G, Nadler'LM, Sharpe AH: Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interIeukin-2 production. J Exp Med 178:2185, 1993
14. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 180:1665, 1994
15. Klarnet JP, Kem DE, Dower SK, Matis LA, Cheever MA, Greenberg PD: Helper-independent CD8+ cytotoxic lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2. J . Immunol 142:2187, 1989
16. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093, 1992
17. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 3:87, 1995
18. Dailey MO, Pillemer E, Weissman IL: Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci USA 79:5384, 1982
19. Cheever MA, Greenberg PD, Irle C, Thompson JA, Urdal DL, Mochizuki DY, Henney CS, Gillis S: Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol 132:2259, 1984
20. Cheever MA, Thompson JA, Britzmann D, Klarnet JP, Greenberg PD: Antigen-driven long-term cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory cells. J Exp Med 163:1110, 1986
21. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995
22. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD: B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 156:1126, 1996
23. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405, 1994
24. Leach DR, Kümmel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734, 1996
25. Fridmen WH, Kourilsky FM: Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia. Nature 224:277,1969
26. Zarling JM, Raich PC, McKeough M, Bach FH: Generation of cytotoxic lymphocytes in vitro against autologous human leukaemia cells. Nature 262:691, 1976
27. Csako G, Binder RA, Kales AN, Neefe JR: Cloning of human lymphocytes reactive with autologous leukemia cells. Cancer Res 40:3218, 1980
28. Montagna D, Arico M, Montini E, Benedetti FD, Maccario R: Identification of HLA-unrestricted CD8+/CD28- cytotoxic T-cell clones specific for leukemic blasts in children with acute leukemia. Cancer Res 55:3835, 1995